Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to -$5.9 million.

  • Bio's Free Cash Flow rose 3487.1% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.5 million, marking a year-over-year increase of 3158.65%. This contributed to the annual value of -$42.6 million for FY2024, which is 269.12% down from last year.
  • Per Bio's latest filing, its Free Cash Flow stood at -$5.9 million for Q3 2025, which was up 3487.1% from -$8.0 million recorded in Q2 2025.
  • Over the past 5 years, Bio's Free Cash Flow peaked at -$5.7 million during Q2 2021, and registered a low of -$14.7 million during Q1 2024.
  • For the 5-year period, Bio's Free Cash Flow averaged around -$9.5 million, with its median value being -$9.8 million (2025).
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 10992.58% in 2022, then soared by 3487.1% in 2025.
  • Quarter analysis of 5 years shows Bio's Free Cash Flow stood at -$9.9 million in 2021, then fell by 11.66% to -$11.0 million in 2022, then dropped by 2.06% to -$11.3 million in 2023, then surged by 30.75% to -$7.8 million in 2024, then increased by 23.93% to -$5.9 million in 2025.
  • Its Free Cash Flow was -$5.9 million in Q3 2025, compared to -$8.0 million in Q2 2025 and -$9.8 million in Q1 2025.